JP2019507758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507758A5 JP2019507758A5 JP2018544853A JP2018544853A JP2019507758A5 JP 2019507758 A5 JP2019507758 A5 JP 2019507758A5 JP 2018544853 A JP2018544853 A JP 2018544853A JP 2018544853 A JP2018544853 A JP 2018544853A JP 2019507758 A5 JP2019507758 A5 JP 2019507758A5
- Authority
- JP
- Japan
- Prior art keywords
- pridopidine
- pharmaceutically acceptable
- use according
- day
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 117
- 229950003764 pridopidine Drugs 0.000 claims description 117
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 230000000626 neurodegenerative effect Effects 0.000 claims description 39
- 208000030533 eye disease Diseases 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 14
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 230000006727 cell loss Effects 0.000 claims description 8
- 229940054534 ophthalmic solution Drugs 0.000 claims description 8
- 239000002997 ophthalmic solution Substances 0.000 claims description 8
- 208000022873 Ocular disease Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 201000004569 Blindness Diseases 0.000 claims description 4
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 4
- 230000005779 cell damage Effects 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical group Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 229940110759 betaxolol ophthalmic solution Drugs 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- 229960000722 brinzolamide Drugs 0.000 claims description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960001222 carteolol Drugs 0.000 claims description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 229960003933 dorzolamide Drugs 0.000 claims description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical group CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 229960000831 levobunolol Drugs 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 229960004083 methazolamide Drugs 0.000 claims description 2
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims description 2
- 229940100655 ophthalmic gel Drugs 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 229960004458 tafluprost Drugs 0.000 claims description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 229940089406 travoprost ophthalmic solution Drugs 0.000 claims description 2
- 229960004317 unoprostone Drugs 0.000 claims description 2
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 229960002704 metipranolol Drugs 0.000 claims 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims 1
- 230000001499 parasympathomimetic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 49
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- -1 metiplanolol Chemical compound 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299290P | 2016-02-24 | 2016-02-24 | |
| US62/299,290 | 2016-02-24 | ||
| PCT/US2017/019266 WO2017147366A1 (en) | 2016-02-24 | 2017-02-24 | Treatment of neurodegenerative eye disease using pridopidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507758A JP2019507758A (ja) | 2019-03-22 |
| JP2019507758A5 true JP2019507758A5 (https=) | 2020-03-26 |
| JP7034488B2 JP7034488B2 (ja) | 2022-03-14 |
Family
ID=59686581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544853A Active JP7034488B2 (ja) | 2016-02-24 | 2017-02-24 | プリドピジンを使用する神経変性眼疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11738012B2 (https=) |
| EP (1) | EP3419622B1 (https=) |
| JP (1) | JP7034488B2 (https=) |
| AU (1) | AU2017223838B2 (https=) |
| CA (1) | CA3015512C (https=) |
| DK (1) | DK3419622T3 (https=) |
| ES (1) | ES2979123T3 (https=) |
| HU (1) | HUE066769T2 (https=) |
| PL (1) | PL3419622T3 (https=) |
| WO (1) | WO2017147366A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US20220062255A1 (en) * | 2016-02-24 | 2022-03-03 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| CN113395964A (zh) | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| AU2020243692B2 (en) * | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| JP7829678B2 (ja) * | 2021-10-11 | 2026-03-13 | プリレニア ニューロセラピューティクス リミテッド | 神経変性眼疾患を治療するためのプリドピジン及びその類似体 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| IL134241A (en) * | 2000-01-27 | 2006-06-11 | Finetech Pharmaceutical Ltd | Process for the preparation of latanoprost |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| CN101711236B (zh) | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| EP2170343A1 (en) | 2007-05-31 | 2010-04-07 | Joseph Weinstock | Treatment of age-related macular degeneration |
| AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| BR112014005389A8 (pt) | 2011-09-07 | 2018-04-03 | Ivax Int Gmbh | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| US20150216850A1 (en) * | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| KR20200031446A (ko) | 2018-09-14 | 2020-03-24 | 삼성전자주식회사 | 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치 |
-
2017
- 2017-02-24 JP JP2018544853A patent/JP7034488B2/ja active Active
- 2017-02-24 EP EP17757261.7A patent/EP3419622B1/en active Active
- 2017-02-24 WO PCT/US2017/019266 patent/WO2017147366A1/en not_active Ceased
- 2017-02-24 ES ES17757261T patent/ES2979123T3/es active Active
- 2017-02-24 AU AU2017223838A patent/AU2017223838B2/en active Active
- 2017-02-24 PL PL17757261.7T patent/PL3419622T3/pl unknown
- 2017-02-24 CA CA3015512A patent/CA3015512C/en active Active
- 2017-02-24 DK DK17757261.7T patent/DK3419622T3/da active
- 2017-02-24 HU HUE17757261A patent/HUE066769T2/hu unknown
- 2017-02-24 US US16/078,929 patent/US11738012B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507758A5 (https=) | ||
| CA2807084C (en) | Preservative free brimonidine and timolol solutions | |
| EP2646010B1 (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| AU2011274245B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| JP2021102626A5 (https=) | ||
| WO2015105144A1 (ja) | ピリジルアミノ酢酸化合物を含む医薬製剤 | |
| US20180318319A1 (en) | Compositions and Methods for Treating Eyes and Methods of Preparation | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| JP2021501803A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| US20200188405A1 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
| JP7346305B2 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| CN115998888A (zh) | 用于治疗青光眼或高眼压症的药物组合物及其用途 | |
| KR20230098630A (ko) | 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물 | |
| JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
| Kish | Old and new drug classes expanding to include glaucoma treatments | |
| TWI896143B (zh) | 一種有效延緩及治療近視的藥物組合物 | |
| Kaplowitz | Updated Medical Treatment | |
| Croasdell | Association for Research in Vision and Ophthalmology (ARVO)-2016 Annual Meeting. Seattle, Washington, USA-April 29-May 5, 2016 | |
| HK40004045A (en) | Preservative free brimonidine and timolol solutions | |
| HK1241269B (zh) | 前列腺素类和一氧化氮供体的组合产品 | |
| Serle | Medical therapy for glaucoma Paul S Lee, Donna J Gagliuso | |
| HK1118211A (en) | Ophthalmologic compositions and use mode thereof | |
| SA06270472B1 (ar) | طريقة لمعالجة النوعين الاولي والثانوي للغلوكوما | |
| HK1190067A (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |